View as an RSS Feed
In Case Of MERS Emergency - Break Glass, Buy Novavax
- Only Novavax has the science and production facilities to appropriately respond to an emerging MERS threat.
- MERS infections are increasing dramatically, with 300 new infections reported by WHO in the last few weeks.
- Investment opportunity is directly related to the number of new infections, and thus can be tracked and measured.
Novavax: A Unique Opportunity
- Predictable Regulatory Approvals and Novel Financing - Equates to Low Risk and High Returns.
- Significant profit opportunity in 3 to 18 months.
- Recent RSV clinical results achieved dramatic breakthroughs in efficacy and safety.
- Federal and Private, NGO investments provide independent votes of confidence.
- Pandemic Flu and emerging MERS threats put Novavax at the vanguard of protecting global health from emerging pandemics.
- Pandora's Acquisition Prospects Jump
- Inventure Foods Demonstrating Fundamental And Technical Strength
- Cold Fusion: A Cure For High Gas Prices
- Is Lihua International Being Shorted Back To China?
- Lihua International, Inc.: Turning Copper Into Gold
- Telestone Tech: Rock Solid Chinese Stock With Huge Potential
- Sangamo's Phase II Results To Be Announced Monday - Expect Good News
- The Wisdom Of The Crowds And Sangamo's Phase II B Clinical Trial Results
- Sangamo's Late Breaking News: Time To Act
- Sangamo's Late Breaking, Game Changing News At ICAAC
- Steve Jobs' Job Went From CEO to COB, But Nothing Has Changed
- Sangamo BioScience: A Real Bargain Below $5
- Sangamo's Inevitable Acquisition/Merger
- Sangamo Biosciences' Game Changing Technology
- A Checklist for Safe Investing in Chinese Stocks